Startseite Kongressberichte & Archiv ELCC 2018 (European Lung Cancer Congress) Interviews Interviews in Cooperation with the Video Journal of Oncology - Part 1
 
 
Fred Hirsch:
2:55
Blueprint Project update: how comparable are the results of different PD-L1 assays?
 
 
3:47
A KEYNOTE on PD-L1 as a predictive biomarker of immunotherapy response: a complex picture
 
Matthew Hatton:
2:32
Cardiac doses of radical radiotherapy impact survival in NSCLC: a real-world analysis
 
Martin Reck:
1:02
Pembrolizumab monotherapy for NSCLC: KEYNOTE-024 update
 
 
2:16
IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
 
 
1:24
Transforming outcomes in advanced lung cancer: immunotherapy in unselected patients
 
 
1:13
A new standard of care for advanced lung cancer: what’s next for pembrolizumab?
 
Marina Garassino:
1:39
Pembrolizumab and epacadostat for NSCLC: ECHO-306/KEYNOTE-715
 
 
1:51
Which NSCLC patients should receive chemotherapy and anti-angiogenics?
 
 
1:25
Treating NSCLC with CNS involvement: TKIs with high penetrance